前列腺癌有利中危、不利中危与极高危分层标准的统一
该回顾性研究纳入单中心2248例接受剂量递增外照射放疗的前列腺癌患者,将NCCN中危分为有利中危与不利中危,高危分为标准高危与极高危。有利中危与低危结局相似,不利中危与标准高危相似,据此提出三组分层系统,各组8年远处转移率与前列腺癌特异性死亡率差异显著,且预测准确性优于现行NCCN三分法。
要点
- 有利中危与低危结局相似,不利中危与标准高危结局相似,可分别合并。
- 新分层三组8年远处转移率为3%、9%、29%,前列腺癌特异性死亡率为1%、4%、13%。
- 改良分层系统对所有结局的预测准确性显著优于现行NCCN三分法。
核心结论
- 将NCCN分层中的有利中危归入低危组、不利中危归入标准高危组,可适度改善结局预测,并可能有助于更好地个体化治疗推荐。
研究设计与样本
- 回顾性研究,纳入单中心2248例接受剂量递增外照射放疗(EBRT)的前列腺癌患者。
- 依据主要Gleason评分、阳性穿刺针数百分比(PPBC)及NCCN中危因素数量,将NCCN中危分为有利中危(FIR)与不利中危(UIR)。
- 依据主要Gleason评分、PPBC、NCCN高危因素数量及T3b-T4期疾病,将NCCN高危分为标准高危(SHR)与极高危(VHR)。
主要发现
- UIR患者较FIR患者的前列腺特异性抗原无复发生存(PSA-RFS,P < 0.001)、无远处转移生存(DMFS,P < 0.001)、前列腺癌特异性死亡(PCSM,P < 0.001)及总生存(OS,P < 0.001)均显著更差。
- VHR患者较SHR患者的PSA-RFS(P < 0.001)、DMFS(P < 0.001)及PCSM(P = 0.001)均显著更差。
- FIR与低危患者结局相似,UIR与SHR患者结局相似。
- EBRT后8年远处转移率在1组、2组、3组分别为3%、9%、29%(P < 0.001),8年PCSM分别为1%、4%、13%(P < 0.001)。
- 改良分层系统对所有结局的预测准确性显著优于目前临床使用的三层NCCN系统。
关键数值与推荐
- 提出分层系统:1组为低危与FIR,2组为UIR与SHR,3组为VHR。
- 1组、2组、3组8年远处转移率分别为3%、9%、29%(P < 0.001)。
- 1组、2组、3组8年PCSM分别为1%、4%、13%(P < 0.001)。
临床怎么用
- 作者认为,将NCCN分层中的FIR归入低危组、UIR归入SHR组,可适度改善结局预测,并可能有助于更好地个体化治疗推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To improve on the existing risk-stratification systems for prostate cancer. PATIENTS AND METHODS: This was a retrospective investigation including 2 248 patients undergoing dose-escalated external beam radiotherapy (EBRT) at a single institution. We separated National Comprehensive Cancer Network (NCCN) intermediate-risk prostate cancer into 'favourable' and 'unfavourable' groups based on primary Gleason pattern, percentage of positive biopsy cores (PPBC), and number of NCCN intermediate-risk factors. Similarly, NCCN high-risk prostate cancer was stratified into 'standard' and 'very high-risk' groups based on primary Gleason pattern, PPBC, number of NCCN high-risk factors, and stage T3b-T4 disease. Patients with unfavourable-intermediate-risk (UIR) prostate cancer had significantly inferior prostate-specific antigen relapse-free survival (PSA-RFS, P < 0.001), distant metastasis-free survival (DMFS, P < 0.001), prostate cancer-specific mortality (PCSM, P < 0.001), and overall survival (OS, P < 0.001) compared with patients with favourable-intermediate-risk (FIR) prostate cancer. Similarly, patients with very high-risk (VHR) prostate cancer had significantly worse PSA-RFS (P < 0.001), DMFS (P < 0.001), and PCSM (P = 0.001) compared with patients with standard high-risk (SHR) prostate cancer. Moreover, patients with FIR and low-risk prostate cancer had similar outcomes, as did patients with UIR and SHR prostate cancer. RESULTS: Consequently, we propose the following risk-stratification system: Group 1, low risk and FIR; Group 2, UIR and SHR; and Group 3, VHR. These groups have markedly different outcomes, with 8-year distant metastasis rates of 3%, 9%, and 29% (P < 0.001) for Groups 1, 2, and 3, respectively, and 8-year PCSM of 1%, 4%, and 13% (P < 0.001) after EBRT. This modified stratification system was significantly more accurate than the three-tiered NCCN system currently in clinical use for all outcomes. CONCLUSION: Modifying the NCCN risk-stratification system to group FIR with low-risk patients and UIR with SHR patients, results in modestly improved prediction of outcomes, potentially allowing better personalisation of therapeutic recommendations.
引用
- Zumsteg ZS, Zelefsky MJ, Woo KM, et al. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer. BJU Int. 2017. PMID: 28464446. doi:10.1111/bju.13903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。